Subtopic Deep Dive
Dual Antiplatelet Therapy in ACS
Research Guide
What is Dual Antiplatelet Therapy in ACS?
Dual Antiplatelet Therapy (DAPT) in Acute Coronary Syndromes (ACS) combines aspirin with P2Y12 inhibitors such as ticagrelor, prasugrel, or clopidogrel to prevent ischemic events post-ACS while balancing bleeding risks.
Landmark trials like PLATO demonstrated ticagrelor superiority over clopidogrel in reducing vascular death, MI, or stroke in ACS patients (Wallentin et al., 2009; 6960 citations). Guidelines from ACCF/AHA and ESC recommend DAPT duration and potency based on these trials and subsequent studies (Levine et al., 2011; Hamm et al., 2011). Over 20,000 citations across key papers shape current standards.
Why It Matters
DAPT optimization reduces stent thrombosis and recurrent MI in post-ACS patients, directly influencing guideline-directed pharmacotherapy worldwide. The PLATO trial showed ticagrelor lowered ischemic events by 16% versus clopidogrel without excess fatal bleeding (Wallentin et al., 2009). PEGASUS-TIMI 54 extended ticagrelor benefits beyond one year, informing prolonged therapy in high-risk cases (Bonaca et al., 2015). APPRAISE-2 highlighted bleeding risks with triple therapy additions like apixaban (Alexander et al., 2011). These findings guide millions of annual ACS treatments.
Key Research Challenges
Balancing Ischemic vs Bleeding Risks
DAPT reduces ischemic events but increases major bleeding, requiring risk stratification tools. PLATO showed ticagrelor benefits but dyspnea and bleeding concerns (Wallentin et al., 2009). PEGASUS-TIMI 54 confirmed long-term bleeding trade-offs (Bonaca et al., 2015).
Optimal DAPT Duration Selection
Guidelines vary 6-12 months or longer based on patient risk, lacking universal predictors. ACCF/AHA PCI guidelines recommend tailored durations (Levine et al., 2011). ESC ACS guidelines emphasize individualized approaches (Hamm et al., 2011).
P2Y12 Inhibitor Potency Choices
Ticagrelor outperforms clopidogrel in ACS per PLATO, but prasugrel data limited in provided papers. Head-to-head trials inform potency but comorbidities complicate selection (Wallentin et al., 2009). COVID-19 era highlighted thrombotic adaptations (Bikdeli et al., 2020).
Essential Papers
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
Lars Wallentin, Richard C. Becker, Andrzej Budaj et al. · 2009 · New England Journal of Medicine · 7.0K citations
In patients who have an acute coronary syndrome with or without ST-segment elevation, treatment with ticagrelor as compared with clopidogrel significantly reduced the rate of death from vascular ca...
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
Glenn N. Levine, Eric Bates, James C. Blankenship et al. · 2011 · Circulation · 3.3K citations
ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)
C Hamm, Jean‐Pierre Bassand, Stefan Agewall et al. · 2011 · European Heart Journal · 3.1K citations
peer reviewed
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
Behnood Bikdeli, Mahesh V. Madhavan, David Jiménez et al. · 2020 · Journal of the American College of Cardiology · 2.9K citations
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: Executive Summary
Patrick T. O’Gara, Frederick G. Kushner, Deborah D. Ascheim et al. · 2012 · Circulation · 2.2K citations
Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction
Marc P. Bonaca, Deepak L. Bhatt, Marc Cohen et al. · 2015 · New England Journal of Medicine · 1.9K citations
In patients with a myocardial infarction more than 1 year previously, treatment with ticagrelor significantly reduced the risk of cardiovascular death, myocardial infarction, or stroke and increase...
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes: Executive Summary
Ezra A. Amsterdam, Nanette K. Wenger, Ralph G. Brindis et al. · 2014 · Circulation · 1.2K citations
The writing
Reading Guide
Foundational Papers
Start with PLATO trial (Wallentin et al., 2009) for ticagrelor evidence; follow with ACCF/AHA PCI Guideline (Levine et al., 2011) and ESC ACS Guideline (Hamm et al., 2011) for recommendations.
Recent Advances
PEGASUS-TIMI 54 (Bonaca et al., 2015) for extended therapy; COMPLETE trial (Mehta et al., 2019) contextualizes PCI strategies; COVID implications (Bikdeli et al., 2020).
Core Methods
RCTs like PLATO compare P2Y12 agents; guidelines synthesize Kaplan-Meier survival, Cox models for risks; meta-analyses aggregate HRs for ischemic/bleeding endpoints.
How PapersFlow Helps You Research Dual Antiplatelet Therapy in ACS
Discover & Search
PapersFlow's Research Agent uses searchPapers and citationGraph to map DAPT literature from PLATO (Wallentin et al., 2009), revealing 6960 citations and forward links to PEGASUS (Bonaca et al., 2015); exaSearch uncovers guideline updates like Levine et al. (2011) and Hamm et al. (2011).
Analyze & Verify
Analysis Agent employs readPaperContent on PLATO abstracts for ticagrelor vs clopidogrel outcomes, verifyResponse with CoVe chain-of-verification to confirm 16% ischemic reduction claims, and runPythonAnalysis for meta-analysis of bleeding rates across Wallentin (2009) and Bonaca (2015) using GRADE evidence grading for high-quality RCTs.
Synthesize & Write
Synthesis Agent detects gaps like long-term DAPT in COVID-ACS via contradiction flagging between Bikdeli (2020) and classic trials; Writing Agent uses latexEditText, latexSyncCitations for guideline-compliant reports, latexCompile for publication-ready docs, and exportMermaid for risk-benefit flowcharts.
Use Cases
"Extract bleeding and ischemic event rates from PLATO and PEGASUS trials for meta-analysis."
Analysis Agent → readPaperContent (Wallentin 2009, Bonaca 2015) → runPythonAnalysis (pandas meta-analysis, matplotlib forest plots) → GRADE-verified event rate tables with statistical outputs.
"Draft guideline summary on DAPT duration post-STEMI with citations."
Synthesis Agent → gap detection (Levine 2011, O’Gara 2012) → Writing Agent → latexEditText (structure summary) → latexSyncCitations (auto-insert) → latexCompile (PDF guideline doc).
"Find code for DAPT risk calculators from related papers."
Research Agent → paperExtractUrls (Mehta 2019) → paperFindGithubRepo → githubRepoInspect → Code Discovery workflow outputs Python risk models linked to multivessel PCI data.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ DAPT papers: searchPapers (ACS+DAPT) → citationGraph → DeepScan 7-step analysis with GRADE checkpoints on Wallentin (2009) efficacy. Theorizer generates hypotheses on personalized DAPT from PLATO/PEGASUS contradictions: readPaperContent → gap detection → theory export. DeepScan verifies guideline adherence across Levine (2011) and Hamm (2011).
Frequently Asked Questions
What defines Dual Antiplatelet Therapy in ACS?
DAPT pairs aspirin with P2Y12 inhibitors (ticagrelor, clopidogrel) post-ACS to prevent thrombosis. PLATO trial established ticagrelor superiority (Wallentin et al., 2009).
What methods prove ticagrelor efficacy over clopidogrel?
PLATO RCT showed 16% reduction in death/MI/stroke with ticagrelor (Wallentin et al., 2009; 6960 citations). Guidelines endorse based on this (Levine et al., 2011).
What are key papers on DAPT in ACS?
PLATO (Wallentin et al., 2009; 6960 citations), PEGASUS (Bonaca et al., 2015; 1923 citations), ACCF/AHA PCI Guideline (Levine et al., 2011; 3289 citations).
What open problems remain in DAPT research?
Optimal duration prediction, bleeding risk mitigation in high-risk groups, and potency selection amid comorbidities. PEGASUS showed long-term trade-offs (Bonaca et al., 2015).
Research Acute Myocardial Infarction Research with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Dual Antiplatelet Therapy in ACS with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers